Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036402 | 0.90 | LCK (0.67) | LCKSRC | |
| SCHEMBL7969699 | 0.85 | LCK (0.85) | LCKSRC | |
| SCHEMBL4041705 | 0.85 | LCK (0.69) | LCKSRC | |
| SCHEMBL7981602 | 0.83 | LCK (1.00) | LCKSRC | |
| SCHEMBL4039987 | 0.82 | LCK (0.71) | LCKSRC | |
| SCHEMBL7980622 | 0.81 | LCK (1.00) | LCK | |
| SCHEMBL4040959 | 0.79 | LCK (0.69) | LCKSRC | |
| SCHEMBL4039941 | 0.78 | LCK (0.60) | LCKSRC | |
| SCHEMBL4036601 | 0.78 | LCK (0.72) | LCK | |
| SCHEMBL4044146 | 0.77 | LCK (0.70) | LCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-1323716-B1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | TAKEDA PHARMACEUTICAL (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-7008950-B1 | Benzofurans as suppressors of neurodegeneration | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-07 | — | — | US | disclosed |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1323716-A1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | Takeda Chemical Industries, Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-0988289-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-29 | — | — | EP | disclosed |
| US-5990109-A | NOVEL COMPOUNDS, METHODS OF THEIR SYNTHESIS, AND THEIR USE IN TREATING VARIOUS TYROSINE KINASE-ASSOCIATED IMMUNOLOGICAL DISORDERS, SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GRAFT VS. HOST DISEASE, LUPUS, PSORIASIS AND ASTHMA | BRISTOL-MYERS SQUIBB CO. (US) | 1999-11-23 | — | — | US | disclosed |
| WO-1998055454-A2 | BENZOFURANS AND BENZOTHOPHENES AS SUPPRESSORS OF NEURODEGENERATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | NES, MKI67, CCNO | LCK 4096/4885SRC 1394/4885 |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | NES, HAT1, PROX1 | LCK 4359/4885SRC 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.